Joan Brugge

Last updated
Joan Brugge
Alma mater
Scientific career
Institutions
Academic advisors Raymond L. Erikson [1]

Joan S. Brugge is the Louise Foote Pfeiffer Professor of Cell Biology and the Director of the Ludwig Center at Harvard Medical School, where she also served as the Chair of the Department of Cell Biology from 2004 to 2014. Her research focuses on cancer biology, and she has been recognized for her explorations into the Rous sarcoma virus, extracellular matrix adhesion, and epithelial tumor progression in breast cancer. [2] [3] [4] [5]

Contents

Education

Brugge originally intended on pursuing a career as a mathematics instructor. While she was attending Northwestern University as an undergraduate student, her sister developed a brain tumor. This event sparked a newfound passion for biology and specifically cancer research. While Brugge was completing her undergraduate degree in biology, she became interested in tumor virology, which refers to the study of how viruses can affect and in some cases produce cancerous cells. [6] [7] This focus led her to the Baylor College of Medicine in Houston, Texas, which housed one of the only virology programs in the country at the time. [2] Brugge graduated with her doctorate degree in virology in 1975. [8]

Career

After the completion of her doctorate degree, Brugge joined Dr. Ray Erikson at the University of Colorado for her postdoctorate work. It was there that she and Tony Purchio discovered the protein product of the Rous Sarcoma virus v-SRC gene. [9] [10] Brugge subsequently identified the protein product of the cellular gene (c-Src) from which v-Src derived. These discoveries were major breakthroughs in cancer research, as v-SRC and c-Src were the first viral and cellular oncoprotein identified and paved the way to subsequent studies on the mechanism of oncogenic transformation.

In 1979, Brugge took an assistant professor position at the State University of New York (SUNY) at Stony Brook, eventually becoming a Professor of Microbiology. She continued her studies on the Rous sarcoma virus (RSV) that she had discovered in her postdoctorate work. Much of her research centered on finding the role of pp60src, which is the protein that is coded for by RSV. [11] [12] [13] Brugge then moved on to the same position at the University of Pennsylvania in 1989. [8] During this time, she was also named an Investigator for the Howard Hughes Medical Institute, which is an assembly of medical scientists and researchers that advances biomedical research for the benefit of the general public. [14]

In 1992, Brugge joined ARIAD Pharmaceuticals in Cambridge, Massachusetts as its Scientific Director. [8] ARIAD primarily focuses on making drugs for the treatment of cancers with limited treatment options. [15] After five years in industry, however, Brugge chose to return to the academic world in order to place a bigger focus on her own research. She took a position as a Professor in the Department of Cell Biology at Harvard Medical School in 1997, and served as the Chair of the department from 2003 to 2014. Brugge has redirected her most recent research efforts because, in her own words, "we were kind of lured into areas that were pretty far from cancer, so I really wanted to go back to cancer." [6] Her lab focuses on elucidating the cellular processes and signaling pathways that are involved in the initiation and progression of epithelial tumors, primarily of the breast and ovary. [4] [16] [3] [17] [18] [19]

Awards and honors

Brugge is a member of the American Society of Cell Biologists (ASCB). She received the society's annual Sandra K. Masur Senior Leadership Award in 2001 [20] and was inducted as a Fellow in 2016. [21] Brugge was awarded an American Cancer Society Research Professorship in 2001, [22] and her work has been funded by the Breast Cancer Research Foundation. [16] Some of Brugge's other recognitions include:

Selected publications

Related Research Articles

<span class="mw-page-title-main">Oncogene</span> Gene that has the potential to cause cancer

An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels.

<span class="mw-page-title-main">Retrovirus</span> Family of viruses

A retrovirus is a type of virus that inserts a DNA copy of its RNA genome into the DNA of a host cell that it invades, thus changing the genome of that cell. After invading a host cell's cytoplasm, the virus uses its own reverse transcriptase enzyme to produce DNA from its RNA genome, the reverse of the usual pattern, thus retro (backwards). The new DNA is then incorporated into the host cell genome by an integrase enzyme, at which point the retroviral DNA is referred to as a provirus. The host cell then treats the viral DNA as part of its own genome, transcribing and translating the viral genes along with the cell's own genes, producing the proteins required to assemble new copies of the virus. Many retroviruses cause serious diseases in humans, other mammals, and birds.

<span class="mw-page-title-main">Tyrosine kinase</span> Class hi residues

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to the tyrosine residues of specific proteins inside a cell. It functions as an "on" or "off" switch in many cellular functions.

<span class="mw-page-title-main">Harold E. Varmus</span> American scientist (born 1939)

Harold Eliot Varmus is an American Nobel Prize-winning scientist. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.

Mouse mammary tumor virus (MMTV) is a milk-transmitted retrovirus like the HTL viruses, HI viruses, and BLV. It belongs to the genus Betaretrovirus. MMTV was formerly known as Bittner virus, and previously the "milk factor", referring to the extra-chromosomal vertical transmission of murine breast cancer by adoptive nursing, demonstrated in 1936, by John Joseph Bittner while working at the Jackson Laboratory in Bar Harbor, Maine. Bittner established the theory that a cancerous agent, or "milk factor", could be transmitted by cancerous mothers to young mice from a virus in their mother's milk. The majority of mammary tumors in mice are caused by mouse mammary tumor virus.

<span class="mw-page-title-main">Howard Martin Temin</span> 20th-century American geneticist

Howard Martin Temin was an American geneticist and virologist. He discovered reverse transcriptase in the 1970s at the University of Wisconsin–Madison, for which he shared the 1975 Nobel Prize in Physiology or Medicine with Renato Dulbecco and David Baltimore.

<span class="mw-page-title-main">J. Michael Bishop</span> American immunologist and microbiologist

John Michael Bishop is an American immunologist and microbiologist who shared the 1989 Nobel Prize in Physiology or Medicine with Harold E. Varmus and was co-winner of 1984 Alfred P. Sloan Prize. He serves as an active faculty member at the University of California, San Francisco (UCSF), where he also served as chancellor from 1998 to 2009.

<span class="mw-page-title-main">Oncovirus</span> Viruses that can cause cancer

An oncovirus or oncogenic virus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term "oncornaviruses" was used to denote their RNA virus origin. With the letters "RNA" removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with "tumor virus" or "cancer virus". The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein.

Rous sarcoma virus (RSV) is a retrovirus and is the first oncovirus to have been described. It causes sarcoma in chickens.

<span class="mw-page-title-main">Viral transformation</span>

Viral transformation is the change in growth, phenotype, or indefinite reproduction of cells caused by the introduction of inheritable material. Through this process, a virus causes harmful transformations of an in vivo cell or cell culture. The term can also be understood as DNA transfection using a viral vector.

<span class="mw-page-title-main">Francis Peyton Rous</span> American scientist (1879–1970)

Francis Peyton Rous was an American pathologist at the Rockefeller University known for his works in oncoviruses, blood transfusion and physiology of digestion. A medical graduate from the Johns Hopkins University, he was discouraged to become a practicing physician due to severe tuberculosis. After three years of working as an instructor of pathology at the University of Michigan, he became dedicated researcher at the Rockefeller Institute for Medical Research for the rest of his career.

The gag-onc fusion protein is a general term for a fusion protein formed from a group-specific antigen ('gag') gene and that of an oncogene ('onc'), a gene that plays a role in the development of a cancer. The name is also written as Gag-v-Onc, with "v" indicating that the Onc sequence resides in a viral genome. Onc is a generic placeholder for a given specific oncogene, such as C-jun..

v-Src is a gene found in Rous sarcoma virus (RSV) that encodes a tyrosine kinase that causes a type of cancer in chickens.

<span class="mw-page-title-main">Proto-oncogene tyrosine-protein kinase Src</span> Mammalian protein found in Homo sapiens

Proto-oncogene tyrosine-protein kinase Src, also known as proto-oncogene c-Src, or simply c-Src, is a non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene. It belongs to a family of Src family kinases and is similar to the v-Src gene of Rous sarcoma virus. It includes an SH2 domain, an SH3 domain and a tyrosine kinase domain. Two transcript variants encoding the same protein have been found for this gene.

<span class="mw-page-title-main">FGR (gene)</span> Protein-coding gene in the species Homo sapiens

Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog, also known as FGR, is a protein which in humans is encoded by the FGR gene.

<span class="mw-page-title-main">Invadopodia</span>

Invadopodia are actin-rich protrusions of the plasma membrane that are associated with degradation of the extracellular matrix in cancer invasiveness and metastasis. Very similar to podosomes, invadopodia are found in invasive cancer cells and are important for their ability to invade through the extracellular matrix, especially in cancer cell extravasation. Invadopodia are generally visualized by the holes they create in ECM -coated plates, in combination with immunohistochemistry for the invadopodia localizing proteins such as cortactin, actin, Tks5 etc. Invadopodia can also be used as a marker to quantify the invasiveness of cancer cell lines in vitro using a hyaluronic acid hydrogel assay.

Peter K. Vogt is an American molecular biologist, virologist and geneticist. His research focuses on retroviruses and viral and cellular oncogenes.

Raymond L. Erikson was a molecular biologist and virologist who noted research on cell growth and regulation. He also served as the John F. Drum American Cancer Society Professor of Cellular and Developmental Biology at Harvard University.

Kimberly W. Anderson is an American chemist. She is the Gill Eminent Professor of Chemical Engineering and Associate Dean for Administration and Academic Affairs in the College of Engineering at the University of Kentucky.

Harry Rubin – February 2, 2020) was an American cell biologist and virologist. He is known for his experimental research on oncoviruses and how cellular microenvironment and cellular aging affect the regulation of cancerous tumors.

References

  1. ↑ "The BRUGGE Lab at Harvard Medical School"
  2. 1 2 Brugge, J. (2011). "At the leading edge of cancer research: An interview with Joan Brugge". Disease Models & Mechanisms. 4 (1): 9–11. doi:10.1242/dmm.007229. PMC   3014341 . PMID   21183482.
  3. 1 2 3 "Joan S. Brugge, PhD | Class of 2014". American Association for Cancer Research. AACR.
  4. 1 2 "Joan S. Brugge, PhD". Dana-Farber/Harvard Cancer Center. NCICCC.
  5. ↑ "Joan Brugge". Harvard Medical School - Department of Cell Biology. The President and Fellows of Harvard College.
  6. 1 2 "Joan Brugge." American Society for Cell Biology 1 (3 Aug. 2009): Print.
  7. ↑ Javier, Ronald T.; Butel, Janet S. (2008). "The History of Tumor Virology". Cancer Research. 68 (19): 7693–7706. doi:10.1158/0008-5472.CAN-08-3301. PMC   3501656 . PMID   18829521.
  8. 1 2 3 "Joan Brugge". The BRUGGE Lab - Selected Biographical Information. The President and Fellows of Harvard College.
  9. ↑ Purchio, A. F.; Erikson, E.; Brugge, J. S.; Erikson, R. L. (1978). "Identification of a polypeptide encoded by the avian sarcoma virus SRC gene". Proceedings of the National Academy of Sciences. 75 (3): 1567–1571. Bibcode:1978PNAS...75.1567P. doi: 10.1073/pnas.75.3.1567 . PMC   411515 . PMID   206909.
  10. ↑ Brugge, Joan S.; Erikson, R. L. (1977). "Identification of a transformation-specific antigen induced by an avian sarcoma virus". Nature. 269 (5626): 346–348. Bibcode:1977Natur.269..346B. doi:10.1038/269346a0. PMID   198667. S2CID   4174483.
  11. ↑ Brugge, Joan S.; Erikson, E.; Erikson, R.L. (1981). "The specific interaction of the Rous sarcoma virus transforming protein, pp60src, with two cellular proteins". Cell. 25 (2): 363–372. doi:10.1016/0092-8674(81)90055-6. PMID   6269742. S2CID   10076530.
  12. ↑ Brugge, Joan S.; Darrow, Diane (1982). "Rous sarcoma virus-induced phosphorylation of a 50,000-molecular weight cellular protein". Nature. 295 (5846): 250–253. Bibcode:1982Natur.295..250B. doi:10.1038/295250a0. PMID   6276761. S2CID   4364105.
  13. ↑ Yonemoto, W.; Filson, A. J.; Queral-Lustig, A. E.; Wang, J. Y.; Brugge, J. S. (1987). "Detection of phosphotyrosine-containing proteins in polyomavirus middle tumor antigen-transformed cells after treatment with a phosphotyrosine phosphatase inhibitor". Molecular and Cellular Biology. 7 (2): 905–913. doi:10.1128/mcb.7.2.905-913.1987. PMC   365149 . PMID   2434835.
  14. ↑ "About Us". Hhmi. Howard Hughes Medical Institute.
  15. ↑ "About ARIAD". ARIAD. ARIAD Pharmaceuticals, Inc.
  16. 1 2 "Joan S. Brugge, PhD". BCRF. The Breast Cancer Research Foundation.
  17. ↑ Debnath, Jayanta; Mills, Kenna R.; Collins, Nicole L.; Reginato, Mauricio J.; Muthuswamy, Senthil K.; Brugge, Joan S. (2002). "The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini". Cell. 111 (1): 29–40. doi: 10.1016/s0092-8674(02)01001-2 . PMID   12372298. S2CID   51808881.
  18. ↑ "Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells". Cancer Cell. doi:10.1016/j.ccr.2011.12.024. PMC   3297962 .
  19. ↑ Schafer, Zachary T.; Grassian, Alexandra R.; Song, Loling; Jiang, Zhenyang; Gerhart-Hines, Zachary; Irie, Hanna Y.; Gao, Sizhen; Puigserver, Pere; Brugge, Joan S. (2009). "Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment". Nature. 461 (7260): 109–113. Bibcode:2009Natur.461..109S. doi:10.1038/nature08268. PMC   2931797 . PMID   19693011.
  20. ↑ "ASCB Sandra K. Masur Senior Leadership Award"
  21. ↑ "ASCB Fellows"
  22. ↑ "American Cancer Society Research and Clinical Research Professors"
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.